# Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

> **NCT06429930** · PHASE1 · RECRUITING · sponsor: **Pharmosa Biopharm Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** L608 Liposomal inhalation suspension
- **DRUG:** Placebo Solution

## Key facts

- **NCT ID:** NCT06429930
- **Lead sponsor:** Pharmosa Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429930, "Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06429930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*